NCT03511170 is a Phase 2 clinical trial of XELIRI in Colorectal Neoplasms, sponsored by Harbin Medical University.

Who is sponsoring NCT03511170?

NCT03511170 is sponsored by Harbin Medical University.

What drugs are being tested in NCT03511170?

Interventions in NCT03511170: XELIRI, XELOX.

What condition does NCT03511170 study?

NCT03511170 studies Colorectal Neoplasms, Chemotherapy.

Is NCT03511170 still recruiting?

NCT03511170 is currently status unknown. Last updated 1 May 2018.

Last reviewed 2018-05-01 · How we verify

NCT03511170

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

XELOX and XELIRI Alternative Regimen as First-line Treatment for Advanced Colorectal Cancer

Status unknown Phase 2 Last updated 1 May 2018

What this trial tests

Phase 2 trial testing XELIRI in Colorectal Neoplasms in 66 participants. Status unknown.

Timeline

1 March 2018

Primary endpoint
1 December 2019

1 June 2020

Quick facts

Lead sponsor	Harbin Medical University
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	66
Start date	1 March 2018
Primary completion	1 December 2019
Estimated completion	1 June 2020
Sites	1 location across China

Drugs / interventions tested

XELIRI — full drug profile →
XELOX — full drug profile →

Conditions studied

Colorectal Neoplasms — all drugs for Colorectal Neoplasms →
Chemotherapy — all drugs for Chemotherapy →

Sponsor

Harbin Medical University

Who can join

Adults 18 to 75, any sex, with Colorectal Neoplasms or Chemotherapy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Colorectal cancer will be resistant to Chemotherapy drugs after treated for a period of time .In the past, the classical treatment regiment was to change other drug after tumor progressed. In theory, the continuous use of such a drug could shortening the patient's drug resistance time. It has been shown that the alternate use of the two drug combinations is reasonable in clinical. This application can not only further improve the curative effect but also significantly reduce the side effects. So the investigators are going to carry out a prospective phase II clinical study. The control group change to second-line treatment after progression of first-line drugs. The experimental group use the first line and the second line,alternately, for every two cycles. The combination of bevacizumab is a first line development, and the second line can still be used .Objective to compare the clinical value of XELOX and XELIRI alternation regimen in the first-line treatment of advanced colorectal cancer.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of XELIRI

Trials testing the same drug.

NCT05669092 — A Phase III Trial of Anus-preservation in Low Rectal Adenocarcinoma Based on MMR/MSI Status · Phase 3 · unknown
NCT04522284 — PRECISE CURATE.AI Pilot Clinical Trial · Phase 1, PHASE2 · unknown

Other recruiting trials for Colorectal Neoplasms

Currently open trials in the same condition.

NCT06983639 — Randomized Trial Comparing Fecal Testing (FIT) to Colonoscopy for Post-polypectomy Surveillance · NA · recruiting
NCT07222800 — Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult · Phase 3 · recruiting
NCT07239479 — DEXDES Trial: Dexmedetomidine-Desflurane Combination in Laparoscopic Colectomy · NA · recruiting
NCT07262840 — Health Behavior Change in High-Risk Colorectal Cancer Individuals · NA · recruiting
NCT07257653 — The Safety and Efficacy of Cetuximab Beta Plus Fruquintinib With or Without Immune Checkpoint Inhibitorrs in First-line · Phase 2 · recruiting

Other Harbin Medical University trials

Trials by the same sponsor.

NCT07471815 — Camrelizumab Plus Risedronate and Chemotherapy for Triple-Negative Breast Cancer: An Exploratory Clinical Study on Mecha · Phase 2 · active not recruiting
NCT07187674 — The Neoadjuvant Treatment of Early High-risk Triple Negative Breast Cancer With HRD Positive With Iparomlimab and Tuvonr · NA · not yet recruiting
NCT07161791 — Camrelizumab, Pirfenidone, and Chemotherapy in the Treatment of Advanced Triple-Negative Breast Cancer · Phase 1, PHASE2 · not yet recruiting
NCT07033624 — Cardiovascular Risk Early Screening and Warning in Harbin : A Prospective Cohort Study · not yet recruiting
NCT06947148 — The Impact of Comprehensive Post Hospital Management Based on DHI on Cardiac Function in Patients With HF · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03511170 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Harbin Medical University
Last refreshed: 1 May 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03511170.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing